Holen Sie sich die Stockscreener-App
20.51
1.53%
0.31
Handel nachbörslich:
20.51
Schlusskurs vom Vortag:
$20.20
Offen:
$20.44
24-Stunden-Volumen:
176.76K
Relative Volume:
0.97
Marktkapitalisierung:
$292.51M
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
-3.35%
1M Leistung:
-4.47%
6M Leistung:
+11.35%
1J Leistung:
-42.42%
1-Tages-Spanne:
$19.67
$21.38
1-Wochen-Bereich:
$18.94
$21.68
52-Wochen-Spanne:
$6.875
$74.49
Neurogene Inc Stock (NGNE) Company Profile
Firmenname
Neurogene Inc
Sektor
Branche
Telefon
(877) 237-5020
Adresse
535 W 24TH STREET, NEW YORK
Vergleichen Sie NGNE mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NGNE
Neurogene Inc
|
20.51 | 288.29M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
392.79 | 100.07B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
580.41 | 59.99B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
448.91 | 58.03B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
653.83 | 39.93B | 3.06B | 1.28B | -614.78M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
321.36 | 36.82B | 3.81B | -644.79M | -669.77M | -6.24 |
Neurogene Inc Stock (NGNE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-06-17 | Eingeleitet | Craig Hallum | Buy |
| 2025-05-16 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2024-06-27 | Eingeleitet | BMO Capital Markets | Outperform |
| 2024-06-11 | Eingeleitet | Robert W. Baird | Outperform |
| 2024-04-29 | Eingeleitet | Leerink Partners | Outperform |
| 2024-03-21 | Eingeleitet | William Blair | Outperform |
| 2024-01-08 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-01-05 | Eingeleitet | Stifel | Buy |
| 2024-01-04 | Eingeleitet | TD Cowen | Outperform |
Alle ansehen
Neurogene Inc Aktie (NGNE) Neueste Nachrichten
Has Neurogene Inc. formed a bullish divergence2025 Retail Activity & Community Verified Swing Trade Signals - Newser
Quantitative breakdown of Neurogene Inc. recent moveJuly 2025 Volume & Daily Entry Point Alerts - Newser
Can trapped investors hope for a rebound in Neurogene Inc.2025 Winners & Losers & Safe Entry Momentum Tips - Newser
What MACD signals say about Neurogene Inc.July 2025 Levels & Reliable Breakout Forecasts - Newser
Has Neurogene Inc. found a price floor2025 Technical Overview & Risk Controlled Swing Trade Alerts - Newser
Neurogene Inc. stock trend outlook and recovery path2025 Short Interest & Fast Moving Trade Plans - Newser
Should you hold or exit Neurogene Inc. nowAnalyst Upgrade & Weekly High Return Forecasts - Newser
How Neurogene Inc. stock performs during market volatilityMarket Trend Review & Low Risk Profit Maximizing Plans - Newser
How moving averages guide Neurogene Inc. tradingWeekly Volume Report & Expert Approved Momentum Trade Ideas - Newser
How to read the order book for Neurogene Inc.Market Movers & Weekly Consistent Profit Watchlists - Newser
What risks could impact Neurogene Inc. stock performanceShort Setup & Daily Oversold Stock Bounce Ideas - Newser
Will Neurogene Inc. bounce back from current support2025 Top Gainers & Weekly High Return Stock Forecasts - Newser
What is HC Wainwright’s Estimate for Neurogene Q3 Earnings? - Defense World
Technical Heatmap Flags Neurogene Inc. for Watch2025 Market Outlook & Free High Return Stock Watch Alerts - sundaytimes.kr
Pattern Scan Adds Neurogene Inc. to WatchlistWeekly Trade Recap & Free Technical Pattern Based Buy Signals - sundaytimes.kr
Short Term Charts Align With Long Term Uptrend in Neurogene Inc.Market Activity Summary & AI Forecast for Swing Trade Picks - thegnnews.com
Applying Elliott Wave Theory to Neurogene Inc.Gap Down & Low Drawdown Momentum Ideas - Newser
Neurogene Inc. Could See a Relief Rally From Support2025 Performance Recap & Free AI Powered Buy and Sell Recommendations - 선데이타임즈
Neurogene Inc. shares fall 5.31% intraday despite positive corporate updates and financial results. - AInvest
Institutional scanner results for Neurogene Inc.Chart-Based Entry Confirmation for Beginners - Newser
Neurogene: Q2 Earnings Snapshot - Connecticut Post
Price momentum metrics for Neurogene Inc. explainedInvestment Roadmap for High Potential Stocks - Newser
Neurogene Inc. Reports Increased Losses Amid R&D Focus - TipRanks
Neurogene Advances NGN-401 Gene Therapy for Rett Syndrome - TipRanks
Neurogene Reports Second Quarter 2025 Financial Results and Highlights Recent Updates - Yahoo Finance
NGNE posts Q2 2025 earnings release and updated corporate presentation - Stock Titan
How to monitor Neurogene Inc. with trend dashboardsFree Low Risk High Return Opportunities - Newser
Using data models to predict Neurogene Inc. stock movementPrice Action Based Buy Zone Forecast - Newser
Is Neurogene Inc. reversing from oversold territorySummary of Reliable Long-Term Trade Models - Newser
What makes Neurogene Inc. stock price move sharplyDaily Exit and Entry Price Prediction - Newser
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Finanzdaten der Neurogene Inc-Aktie (NGNE)
Es liegen keine Finanzdaten für Neurogene Inc (NGNE) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
0.41%
0.88%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):